On June 15, 2026, Brian Daniel Webster, who serves as both President and Chief Executive Officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), completed a transaction involving the sale of 15,000 common shares. The aggregate value of this divestment reached $312,142. The shares were liquidated at prices fluctuating between $20.5400 and $21.3900, resulting in a weighted average execution price of $20.8095 per share. This sale was conducted under the parameters of a Rule 10b5-1 trading plan, which the executive adopted on September 29, 2025. Following the completion of this transaction, Mr. Webster retains direct ownership of 395,467 common shares in Kestra Medical Technologies, Ltd.
The timing of this sale occurs against a backdrop of mixed market performance for the company. The stock currently trades at $19.08, representing a decline of 28% year-to-date. However, the underlying business fundamentals have demonstrated significant expansion, with revenue growth reaching 59% over the last twelve months. According to InvestingPro analysis, KMTS is currently considered overvalued relative to its Fair Value, yet the company maintains a robust balance sheet characterized by holding more cash than debt.
Recent corporate developments have placed Kestra Medical Technologies in the financial spotlight. The company recently reported fiscal third-quarter results that showed revenue nearly 7% above market expectations. Additionally, the firm reported strong gross margin performance, with an adjusted EBITDA loss that exceeded analyst anticipation. These financial metrics have prompted Piper Sandler to reiterate an Overweight rating on the stock and establish a $30.00 price target. The firm cited these impressive results as a primary factor in their positive outlook and expects revenue upside in the fiscal fourth quarter ending in April, driven by an expanded sales force.
Market sentiment has further been bolstered by BTIG, which has also maintained a positive outlook on Kestra Medical Technologies. BTIG reiterated a Buy rating and set a $32.00 price target. The firm recently engaged in virtual meetings with Kestra’s top executives, including President and CEO Brian Webster, to discuss future prospects. Both Piper Sandler and BTIG express optimism regarding the company’s performance, with BTIG’s interactions with management reinforcing their confidence in the stock. These developments indicate a strong interest from analysts in Kestra Medical’s growth trajectory.
Investors evaluating Kestra Medical Technologies can access one of over 1,400 comprehensive Pro Research Reports available for US equities, which transform complex data into actionable intelligence. The company is included in AI-picked strategies that evaluate KMTS alongside thousands of other companies every month using 100+ financial metrics. This analysis looks beyond popularity to assess fundamentals, momentum, and valuation, identifying stocks that offer the best risk-reward based on current data.